Pfizer may try to take Lipitor OTC, but history is against it
This article was originally published in Scrip
Executive Summary
There is a buzz in the US that Pfizer could be interested in obtaining FDA approval of an over-the-counter (OTC) version of its blockbuster cholesterol-lowering product Lipitor (atorvastatin), but almost immediately the same old concerns about how difficult a statin switch can be cropped up.